Hellenic journal of nuclear medicine最新文献

{"title":"Study of serum vitamin D levels in patients with diabetic polyneuropathy using radioimmunoassay method.","authors":"Anastasia Pistola, Evangelos Karathanos, Theocharis Konstantinidis, Dimitrios Papazoglou, Christina Tsigalou, Athanasios Zissimopoulos","doi":"10.1967/s002449912800","DOIUrl":"10.1967/s002449912800","url":null,"abstract":"<p><strong>Objective: </strong>Diabetic polyneuropathy (DPN) is a common and disabling complication of type 2 diabetes mellitus (T2DM). Vitamin D deficiency has been implicated as a potential modifiable risk factor. This study aimed to investigate the relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and DPN using the radioimmunoassay (RIA) method.</p><p><strong>Subjects and methods: </strong>One hundred twenty T2DM patients (80 with DPN and 40 without neuropathy) have been enrolled, while 40 healthy volunteers served as group control. Neuropathy diagnosis was based on clinical assessment (through Michigan neuropathy screening instrument (MNSI) - both questionnaire and examination) and nerve conduction studies. Serum 25(OH)D levels were quantified using RIA.</p><p><strong>Results: </strong>Vitamin D levels were significantly lower in DPN patients (mean 13.2ng/mL) compared to diabetic (18.3ng/mL) and healthy controls (31.2ng/mL, P<0.001). Vitamin D deficiency (<10ng/mL) was found in 72.5% of DPN patients. Apart from severe neuropathy, other factors (age, body mass index -BMI- and HbA1c) have all been mildly inversely correlated to Vitamin D levels.</p><p><strong>Conclusion: </strong>Vitamin D deficiency is significantly associated with the presence and severity of DPN. These findings support the clinical value of assessing and potentially improving vitamin D status in diabetic patients, particularly in those with severe neuropathy.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"90-95"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of radiation on living beings.","authors":"Andreas Otte","doi":"10.1967/s002449912805","DOIUrl":"10.1967/s002449912805","url":null,"abstract":"<p><p>This overview covers the effects of radiation on living organisms, including risks and legal requirements. It defines basic radiation terms, such as ionization, activity, energy dose, or equivalent dose, and explains direct and indirect radiation effects. It also lists foods that should be avoided after a reactor accident, including the topic of iodine prophylaxis.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"145-148"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of PET/CT uptake in the salivary glands in T1N0M0-T2N0M0 glottic cancer.","authors":"Yukinori Okada, Tatsuhiko Zama, Tomohiro Itonaga, Ryuji Mikami, Mtsuru Okubo, Shinji Sugahara, Shiho Wada, Masumi Kawaguchi, Tsubasa Kawamoto, Masanori Ishida, Motoki Nakai, Koichiro Abe, Mana Yoshimura, Takashi Kodama, Masahiko Kurooka, Kazuhiro Saito","doi":"10.1967/s002449912812","DOIUrl":"https://doi.org/10.1967/s002449912812","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to identify factors influencing salivary gland uptake in fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT).</p><p><strong>Subjects and methods: </strong>We retrospectively reviewed patients aged 20-95 years diagnosed with T1N0M0 or T2N0M0 glottic carcinoma between July 2019 and March 2025, who underwent PET/CT for initial staging and radiotherapy planning. Maximum standardized uptake value (SUVmax) and total lesion glycolysis (TLG) were measured and compared based on gender, smoking history, hypertension, diabetes mellitus, dyslipidemia, stage, and primary tumor site.</p><p><strong>Results: </strong>A total of 61 patients were included (mean age, 68.3±12.4 years; 57 male, 4 female). The cohort included 41 patients with T1N0M0 and 20 with T2N0M0 disease. Hypertension status was negative in 32, positive in 28, and unknown in 1; diabetes status was negative in 54, positive in 6, and unknown in 1; dyslipidemia status was negative in 51, positive in 9, and unknown in 1. Smoking history was negative in 7, positive in 53, and unknown in 1. Primary tumor accumulation was observed in 44 patients, while 17 showed no uptake at the primary site. The mean SUVmax of the right submandibular gland was 3.16±0.70 on the left, it was 3.05±0.76. In the right gland, median SUVmax was significantly higher in patients without hypertension 3.350 than in those with hypertension 2.725; P<0.01). In the left gland, median SUVmax was significantly higher in patients without hypertension 3.18 than in those with hypertension 2.56; P<0.01.</p><p><strong>Conclusion: </strong>In T1N0M0-T2N0M0 glottic carcinoma, ¹⁸F-FDG uptake in the submandibular glands is reduced in patients with hypertension.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"28 2","pages":"137-144"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric signet ring cell carcinoma with ureteral metastasis as the first manifestation detected by ⁶⁸Ga-FAPI PET/CT.","authors":"Yuhong Liu, Jia Deng, Yue Chen, Huipan Liu, Jianwen Zhang","doi":"10.1967/s002449912811","DOIUrl":"10.1967/s002449912811","url":null,"abstract":"<p><p></p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"183-184"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of ²²⁵Ac-PSMA RLT targeted therapy for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.","authors":"Huajun Liu, Ma Jiao, Junzheng Wang, Chunyin Zhang","doi":"10.1967/s002449912806","DOIUrl":"10.1967/s002449912806","url":null,"abstract":"<p><strong>Objective: </strong>Using radiolabeled prostate-specific membrane antigen (PSMA) ligands for the treatment of metastatic prostate cancer is a promising therapeutic approach. This systematic review and meta-analysis aims to assess the efficacy and safety of actinium-225 (²²⁵Ac)-PSMA radioligand therapy (RLT) for prostate cancer.</p><p><strong>Materials and methods: </strong>The systematic review and meta-analysis adheres to the preferred reporting items for systematic reviews and meta-analyses (PRISMA). Searches were conducted in databases including PubMed, Web of Science, Medline, CNKI, and VIP, for studies related to ²²⁵Ac-PSMA RLT for prostate cancer from inception until April 2024. The primary endpoint was the therapeutic effect as measured by post-treatment biochemical response evaluation criteria, while secondary endpoints included evaluating overall survival (OS), progression-free survival (PFS), molecular responses.</p><p><strong>Results: </strong>A total of 17 studies involving 1042 patients were included. The pooled proportion of patients with PSA reduction was 85% (95% confidence interval [CI]: 80%-91%), and the pooled rate of PSA reduction >50% was 66% (95% CI: 58%-75%). The combined values for OS and PFS were 13.79 months (95% CI: 11.11-16.48 months) and 9.67 months (95% CI: 6.99-12.35 months), respectively. The molecular response rate was 71% (95% CI: 56-87%). The most common side effect of ²²⁵Ac-PSMA RLT was xerostomia, accounting for 63.5%. Anemia, leukopenia, thrombocytopenia, and renal toxicity were observed in 54.3%, 30.4%, 31.8%, 32.0%, respectively.</p><p><strong>Conclusion: </strong>Actinium-225 -PSMA RLT is an effective and safe treatment for metastatic castration-resistant prostate cancer (mCRPC) patients, with a low incidence of treatment-related adverse reactions. Additionally, a history of lutetium-177 (¹⁷⁷Lu) treatment may have an impact on PSA reduction in mCRPC patients.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"149-167"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study on the diagnostic value of ¹⁸F-FDG PET/CT imaging and integrated PET/MR imaging in pediatric tumors.","authors":"Xuemei Sun, Jiahe Gu","doi":"10.1967/s002449912804","DOIUrl":"10.1967/s002449912804","url":null,"abstract":"<p><strong>Objective: </strong>To analyze and compare the diagnostic value of fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) imaging and integrated PET/magnetic resonance imaging (MR) in pediatric tumors.</p><p><strong>Subjects and methods: </strong>A retrospective analysis was conducted on the clinical data of 61 pediatric patients with malignant tumors admitted to our hospital from September 2022 to December 2023. All patients underwent pathological examinations as well as ¹⁸F-FDG PET/CT and integrated PET/MR imaging. The pathological diagnosis results were used as the gold standard. Pearson correlation analysis, Bland-Altman analysis, and t-tests were used to compare the maximum standardized uptake value (SUVmax), signal-to-noise ratio (SNR), and target-to-background ratio (T/B) between the two methods. Chi-square tests were employed to compare the diagnostic efficacy differences of each index.</p><p><strong>Results: </strong>Among the 61 pediatric malignant tumor patients, a total of 417 lesions were detected, of which 363 lesions showed high uptake on both PET/MR and PET/CT. Among the remaining 54 PET-negative lesions, 9 were CT-positive but MR-negative, including 6 in the lungs and 3 in the vertebrae, while 12 lesions were MR-positive but CT-negative, including 5 in the liver, 4 in the brain, and 3 in the breasts. No statistically significant difference was found in the PET positivity rate or diagnostic results between the two devices (P<0.05). Bland-Altman analysis showed that the background uptake of PET/MR images was lower than that of PET/CT, and the SNR was higher (P<0.05); the SUVmax of the lesions on PET/MR was higher than that on PET/CT (P<0.05); the T/B value of PET/MR images was higher than that of PET/CT (P<0.05). In terms of correlation, the SUVmax, SNR, and T/B values between PET/MR and PET/CT were positively correlated (r=0.919, 0.507, 0.698, P<0.05).</p><p><strong>Conclusion: </strong>In the diagnosis of pediatric malignant tumors, PET/MR and PET/CT have relatively consistent lesion detection rates. PET/MR images have a higher SNR and better resolution, making them more advantageous than PET/CT for evaluating lesions in the liver, brain, and other soft tissue organs, thus warranting clinical application.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"131-136"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness and reliability of ¹⁸I-6-β-iodomethyl- norcholesterol (NP-59), adrenal cortex scintigraphy in discrimination between adenoma and hyperplasia in case of a patient with primary hyperaldosteronism (PH) without discontinuation of antihypertension therapy.","authors":"Evangelos Karathanos, Irini Giagourta, Agaristi Kaspiri","doi":"10.1967/s002449912809","DOIUrl":"10.1967/s002449912809","url":null,"abstract":"<p><p>Clear iodine-131 (¹⁸I)-6-β-iodomethyl- norcholesterol aldosterinoma finding, proven on biopsy, without prior discontinuation of spironolactone (due to high blood pressure) reveals no changes on scintigraphic sensitivity.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"176-180"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-pentixafor for PET imaging of chemokine receptor 4 expression in lymphoproliferative diseases and solid tumors.","authors":"Tingwei Meng, Qingqing Pan, Yaping Luo","doi":"10.1967/s002449912803","DOIUrl":"10.1967/s002449912803","url":null,"abstract":"<p><strong>Objective: </strong>Gallium-68 (⁶⁸Ga)-pentixafor, a novel positron emission tomography (PET) tracer with high affinity for C-X-C motif chemokine receptor 4 (CXCR4), has recently been introduced in order to assess the CXCR4 expression status in vivo. This study is to investigate the role of ⁶⁸Ga-pentixafor in detecting various tumors with mice models and to provide references to clinical studies.</p><p><strong>Materials and methods: </strong>Gallium-68-pentixafor and fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) PET was performed in opm-2 (lymphoma), daudi (myeloma) and panc1 (pancreatic cancer)-bearing mice. Tumor and background tissue uptake between ⁶⁸Ga-pentixafor and ¹⁸F-FDG PET were compared. Gallium-68-pentixafor PET/computed tomography (CT) was performed in four patients with lymphoma and three patients with multiple myeloma, and ¹⁸F-FDG PET/CT was performed as a reference.</p><p><strong>Results: </strong>The uptake of ⁶⁸Ga-pentixafor in background tissues including muscle, liver and kidneys were all lower than those of ¹⁸F-FDG. The uptake of ⁶⁸Ga-pentixafor in the tumors of lymphoma and myeloma-bearing xenografts was comparable or higher than those of ¹⁸F-FDG. However, the tumors of panc-1 xenografts had much lower uptake of ⁶⁸Ga-pentixafor than those in lymphoma and myeloma-bearing mice, and it was also significantly lower than those of ¹⁸F-FDG. The high uptake of ⁶⁸Ga-pentixafor in vivo was confirmed by the high expression of CXCR4 in tumors with immunochemical analysis. Gallium-68-pentixafor PET/CT in patients with marginal zone lymphoma (MZL) and myeloma showed more intense uptake and more extensive involvement than ¹⁸F-FDG PET/CT did. Gallium-68-pentixafor and ¹⁸F-FDG PET/CT showed comparable uptake in the patient with follicular lymphoma.</p><p><strong>Conclusion: </strong>Gallium-68-pentixafor is a promising agent for the evaluation of lymphoproliferative diseases.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"124-130"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG parameters as therapy response predictors in patients with diffuse large B-cell lymphoma: A single centre experience.","authors":"Milica Kotur, Nikola Pantić, Isidora Grozdić Milojević, Amin Mehmedović, Nikola Andrejić, Milica Stojiljković, Jelena Petrović, Dragana Šobić Šaranović, Vera Artiko, Strahinja Odalović","doi":"10.1967/s002449912802","DOIUrl":"10.1967/s002449912802","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to determine the importance of different fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography with computed tomography (PET/CT) semi-quantitative and quantitative parameters, as well as various clinical and demographic parameters, in predicting disease outcomes and response to therapy in patients with diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Subjects and methods: </strong>The study included 64 patients diagnosed with DLBCL who underwent ¹⁸F-FDG PET/CT imaging between January 2020 and April 2023. Each patient underwent both an initial ¹⁸F-FDG PET/CT and an interim ¹⁸F-FDG PET/CT after 2 or 4 cycles of chemotherapy. The Deauville score (DS) was calculated for each patient. Progression-free survival (PFS) was defined as the time from the date of diagnosis to the first appearance of metabolic or morphological progression of pre-existing lesions and/or the appearance of new lesions detected on interim ¹⁸F-FDG PET/CT or follow-up radiological imaging, as well as in cases of death due to the underlying disease or until the end of the clinical follow-up period.</p><p><strong>Results: </strong>Among the clinical-demographic parameters analyzed, the only significant predictive factor was the international prognostic index (IPI) score, categorized by group. Of the ¹⁸F-FDG PET/CT parameters examined, DS showed strong statistical significance in both univariate and multivariate analyses. While maximum standardized uptake value (SUVmax) and peak SUV (SUVpeak) were statistically significant in the univariate analysis. Progression-free survival was longer in patients with an IPI ≤2 and DS ≤3, compared to those with higher IPI and DS.</p><p><strong>Conclusion: </strong>The results of this study showed that the early metabolic response to therapy assessed on the basis of interim ¹⁸F-FDG PET/CT is a significant independent predictive factor for disease outcome in patients with DLBCL.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"115-123"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative insights into mild cognitive impairment: A clinical case study with ¹⁸F-FDG and amyloid PET imaging.","authors":"Shiv Patil, Eric M Teichner, Robert C Subtirelu, Arjun B Ashok, Talha Khan, Alexander Gerlach, Raj Patel, Lancelot Herpin, Moein Moradpour, Thomas Werner, Andrew Newberg, Mona Elisabeth Revheim, Abass Alavi","doi":"10.1967/s002449912807","DOIUrl":"10.1967/s002449912807","url":null,"abstract":"<p><p>Early detection of mild cognitive impairment (MCI) is crucial for initiating therapeutic interventions that may slow or prevent further cognitive deterioration. Mild cognitive impairment represents a transitional phase between normal cognitive aging and more severe forms of dementia, such as Alzheimer's disease (AD). Positron emission tomography (PET) can provide insight into the pathophysiology and progression of neurodegenerative processes associated with dementia and MCI using either fluorine-18 (¹⁸F)-florbetapir, which detects beta-amyloid plaque burden, or ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG), which measures glucose metabolism. However, there are limited comparative studies using the two radiotracers to quantify cognitive decline. This case study presents an 83-year-old female with a clinical diagnosis of MCI and a mini-mental state examination (MMSE) score of 26, at the lower boundary for normal cognitive function; she was assessed with PET/computed tomography (CT) using both radiotracers. Although global assessments did not reveal significant abnormalities, localized findings showed hypometabolism in key brain regions, such as the posterior cingulate cortex, and beta-amyloid plaque accumulation in the anterior cingulate cortex. These results highlight the limitations of conventional cognitive assessments, like the MMSE, and underscore the potential value of PET imaging as a complementary diagnostic tool. The study supports the role of ¹⁸F-FDG as a stronger indicator of cognitive impairment due to its correlation with cognitive scores, while recognizing the need for further research to evaluate the predictive value of both PET tracers in early MCI detection and their potential to improve diagnostic accuracy.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"168-172"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}